<DOC>
	<DOCNO>NCT02251951</DOCNO>
	<brief_summary>The investigator propose study efficacy safety nab-Paclitaxel Phase II trial patient locally advance metastatic adenocarcinoma stomach gastro-esophageal junction</brief_summary>
	<brief_title>Nab-Paclitaxel Salvage Treatment Locally Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description>Adenocarcinomas stomach gastrointestinal junction refractory/resistant 1st line chemotherapy consider orphan disease limit ( ) treatment option . The promising result Nab-Paclitaxel derive preclinical study clinical trial conduct breast cancer patient open field develop therapeutic approach cancer type usually treat taxanes gastric GEJ adenocarcinoma . We design phase II study order evaluate effect nab-Paclitaxel salvage treatment patient advance cancer stomach GEJ previously treat DCF regimen .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age &gt; 18 year old Disease progression treatment DCF regimen Assessable target lesion ( ) define RECIST criterion ECOG performance status ≤ 1 Estimated life expectancy 3 month Serum bilirubin le 1.5 time upper normal limit Aspartate Aminotransferase Alanine Aminotransferase less 2.5 time upper normal limit Creatinine Clearance ≥50 ml/min Neutrophil count 1.5x 109 /L Platelet count 100x 109 /L Hemoglobin 8g/dL Before patient enrollment , write informed consent must give accord Good Clinical Practice guideline national/local regulation . Gastrointestinal bleed Clinically relevant , symptomatic excessive amount ascites result patient 's discomfort CNS metastases Subject pregnant breast feeding , plan become pregnant within 6 month end treatment Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment Known hypersensitivity reaction component treatment Active infection malnutrition bowel obstruction Legal incapacity limit legal capacity Definite contraindication use corticosteroid History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan Chronic inflammation bowel Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrollment Medical psychological condition opinion investigator would permit subject complete study sign meaningful informed consent Second primary tumor nonmelanoma skin cancer situ cervical cancer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Stomach</keyword>
	<keyword>Gastro-Esophageal Junction</keyword>
	<keyword>Salvage treatment</keyword>
	<keyword>Nab-paclitaxel</keyword>
</DOC>